Basis Names Kathryn A. O’Donnell, PhD to Lead Scientific Advisory Board
NEW YORK, July 9, 2024 /PRNewswire/ — The Lung Most cancers Analysis Basis (LCRF) is happy to announce the appointment of Kathryn A. O’Donnell, PhD, as its new Scientific Advisory Board (SAB) chair, efficient July 1, 2024. Dr. O’Donnell succeeds Katerina Politi, PhD, who has served as chair of LCRF’s SAB since 2019.
Kathryn (Kate) O’Donnell, PhD, is an Affiliate Professor within the Division of Molecular Bihology at UT Southwestern Medical Heart and co-leader of the Growth and Most cancers Program within the Harold C. Simmons Complete Most cancers Heart. She obtained her B.S. in genetics from Cornell College and her PhD in human genetics from Johns Hopkins Faculty of Drugs, working with Chi Dang on the features of the MYC oncogene, probably the most essential drivers of human malignancy. Following graduate college, she joined Jef Boeke’s laboratory at Johns Hopkins and developed modern approaches to establish genes that contribute to most cancers and should characterize new therapeutic targets. In 2011, Kate was recruited to UT Southwestern Medical Heart as an Assistant professor within the Division of Molecular Biology and a Most cancers Prevention and Analysis Institute of Texas (CPRIT) Scholar. Since establishing her unbiased laboratory, Dr. O’Donnell has made essential contributions to our understanding of most cancers initiation and development. She has found new most cancers genes, together with oncogenic cell floor proteins which may be targetable with therapeutic antibodies. Her present work is targeted on understanding the mechanisms that contribute to lung tumor growth, the regulation of immune checkpoint pathways, and making use of insights from these research in the direction of the event of latest therapies for lung most cancers. Dr. O’Donnell has served as a member of LCRF’s SAB since 2022.
“I’m thrilled and honored to chair LCRF’s Scientific Advisory Board and I look ahead to working with my colleagues on the Scientific Advisory Board, the Board of Administrators, and the wonderful workers and management at LCRF to proceed funding distinctive lung most cancers analysis,” mentioned O’Donnell.
“We’re excited for Dr. O’Donnell to take the reins of the SAB from Dr. Politi,” remarked Aubrey Rhodes, LCRF’s govt director. “Dr. Politi leaves huge sneakers to fill. Her management has made LCRF’s analysis program what it’s at present – funding modern analysis with the best potential to handle unmet want and enhance outcomes for the lung most cancers neighborhood. Her efforts had been integral in growing a number of multi-year, multi-million-dollar analysis partnerships which have accelerated the tempo of lung most cancers analysis. Underneath her management, the SAB developed a long-term imaginative and prescient via strategic planning and its analysis roadmap, which guides the muse’s analysis investments. She has additionally strived to extend the range of the SAB. We’re grateful for her service and are particularly grateful that she is going to stay on our SAB and Board of Administrators, assuring a clean transition for Dr. O’Donnell into her new function.”
Katerina Politi, PhD, Professor of Pathology and Inside Drugs at Yale Faculty of Drugs, has led LCRF’s SAB for 5 years, overseeing the funding of greater than $11 million in lung most cancers analysis grants in addition to the event of LCRF’s Analysis Roadmap and the founding of the group’s Analysis Advocates volunteer group. She is a celebrated researcher herself, and a previous beneficiary of LCRF’s early investigator grant awards, which give her a singular perspective on each the method and the impression of early funding on a scientist’s profession. Dr. Politi continues as a mentor to different researchers and a companion to LCRF’s board and workers.
“Dr. O’Donnell is a superb scientist and can proceed to construct upon LCRF’s legacy of supporting lung most cancers researchers and novel, modern analysis concepts,” says Dr. Politi. “I am assured that she is going to lead the SAB to realize LCRF’s analysis priorities and enhance outcomes for folks with lung most cancers.”
In regards to the Lung Most cancers Analysis Basis (LCRF)
The Lung Most cancers Analysis Basis® (LCRF) is the main nonprofit group centered on funding modern, high-reward analysis with the potential to increase survival and enhance high quality of life for folks with lung most cancers. LCRF’s mission is to enhance lung most cancers outcomes by funding analysis for the prevention, prognosis, remedy, and remedy of lung most cancers. So far, LCRF has funded 419 analysis grants, totaling practically $44 million, the very best quantity supplied by a nonprofit group devoted to funding lung most cancers analysis. For extra data, go to lcrf.org.
Contact:
Sheila Sullivan
Sr. Director, Advertising & Communications, LCRF
[email protected]
SOURCE Lung Most cancers Analysis Basis
